Prostate Cell News Volume 7.23 | Jun 24 2016

TOP STORY

Identification of an NKX3.1-G9a-UTY Transcriptional Regulatory Network that Controls Prostate Differentiation

The authors showed that loss of function of Nkx3.1 in mouse prostate results in down-regulation of genes that are essential for prostate differentiation, as well as up-regulation of genes that are not normally expressed in prostate. [Science] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer

Scientists demonstrated that in cell lines and patient-derived tumor-initiating cells (TICs), BMI-1 expression is upregulated and associated with stem cell-like traits. From a screened library, they identified a number of post-transcriptional small molecules that target BMI-1 in prostate TICs. [Clin Cancer Res] Abstract

Collapsin Response Mediator Protein-1 (CRMP1) Acts as an Invasion and Metastasis Suppressor of Prostate Cancer via its Suppression of Epithelial–Mesenchymal Transition and Remodeling of Actin Cytoskeleton Organization

Researchers report that CRMP1 can act as a suppressor of tumorigenicity and metastasis in prostate cancer cells. They demonstrated that CRMP1 exhibited a decreased expression pattern in high-grade prostate cancer tissues and many prostate cancer cell lines, and its downregulation in cancer cells was attributed to histone deacetylation and direct repression of its gene by the epithelial–mesenchymal-transition regulator Snail. [Oncogene] Abstract

Dietary Flavonoid Fisetin Increases Abundance of High-Molecular-Mass Hyaluronan Conferring Resistance to Prostate Oncogenesis

HPLC-ESI-MS analysis of tumor xenografts from fisetin treated animals identified several metabolic targets with hyaluronan (HA) as the most affected. Efficacy of fisetin on HA was then evaluated in vitro and also in vivo in the transgenic TRAMP mouse model of prostate cancer. [Carcinogenesis] Abstract

Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth

Investigators determined the bone-enriching capabilities of monomethyl auristatin E phosphate, a derivative of the potent antimitotic monomethyl auristatin E. [Prostate] Abstract

Proliferation of Prostate Stromal Cell Induced by Benign Prostatic Hyperplasia Epithelial Cell Stimulated with Trichomonas vaginalis via Crosstalk with Mast Cell

Researchers investigated whether mast cells reacted with the culture supernatant of BPH epithelial cells infected with T. vaginalis may induce the proliferation of prostate stromal cells. [Prostate] Abstract

The Cannabinoid WIN 55,212-2 Prevents Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells

Scientists determined the influence of the cannabinoid WIN 55,212-2 on the neuroendocrine differentiation of prostate cancer cells. [Prostate Cancer Prostatic Dis] Abstract

Biosynthesis, Antibacterial Activity and Anticancer Effects against Prostate Cancer (PC-3) Cells of Silver Nanoparticles Using Dimocarpus Longan Lour. Peel Extract

The authors demonstrated the biosynthesis, antibacterial activity, and anticancer effects of silver nanoparticles using Dimocarpus Longan Lour. peel aqueous extract. The cytotoxicity effect was explored on human prostate cancer PC-3 cells in vitro by trypan blue assay. [Nanoscale Res Lett] Full Article

CLINICAL RESEARCH

Docetaxel-Related Toxicity in Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer

The authors conducted a retrospective analysis evaluating differences in toxicity based on the clinical state that docetaxel was used. Patients initiating docetaxel between 1/1/2014 and 7/15/2015 were included, with the former date chosen to coincide with the press release for the first metastatic hormone-sensitive prostate cancer study that showed a survival benefit with early docetaxel; ensuring contemporary docetaxel-treated cohorts. [Med Oncol] Abstract

A Comprehensive Review of Genomic Landscape, Biomarkers and Treatment Sequencing in Castration-Resistant Prostate Cancer

Schematically, progression to hormone-naïve prostate cancer and its castration-resistant state (CRPC) could be divided in two distinct pathways, either dependent or independent of the androgen receptor activity. Nevertheless, because the better knowledge of the genetic landscape of CRPC is under way, limited clinical applications are available at the moment, underlying the usefulness of prognostic and predictive biomarkers in daily practice. [Cancer Treat Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Selexis SA announced that Progenics Pharmaceuticals, Inc. has entered into a commercial license agreement for the use of Selexis’ technology and proprietary CHO-K1 cell line. [Selexis SA] Press Release

Prostate Cancer Foundation Announces 24 New Young Investigator Awards

The Prostate Cancer Foundation is pleased to announce 24 new Young Investigator Awards to pioneer increasingly precise treatments and faster cures for prostate cancer. [The Prostate Cancer Foundation] Press Release

Researchers Reeling as UK Votes to Leave EU

It was the result that most scientists didn’t want. The United Kingdom’s vote to leave the European Union has plunged it into political and economic uncertainty — and left researchers worried over the future of their funding and collaborations, the UK’s participation in major European research programs, and the freedom of movement and employment status of thousands of scientists. [Nature News] Editorial

NEW 2016 World Cancer Congress
October 31-November 3, 2016
Paris, France

Visit our events page to see a complete list of events in the prostate cell community.

NEW Faculty Positions – Cancer Immunology (University of New Mexico Health Science Center)

NEW Postdoctoral Position – Molecular Biology/Prostate Cancer (FIBICO)

NEW Researcher – Urology (FIBICO)

NEW Postdoctoral Associate – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute)

NEW Postdoctoral Scientist – Cancer Biology (Medical Research Council)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Research (University of California – San Francisco)

Postdoctoral Fellow – Signaling and Epigenetic Regulation (Medical University of South Carolina)

Postdoctoral Fellow – Prostate Cancer and Metabolism (Cleveland Clinic)

Postdoctoral Fellow – Cell Cycle Regulation in Prostate and Pancreatic Cancer (Purdue University)

Postdoctoral Fellow – Cancer Genomics (Henry Jackson Foundation)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.